BridgeMD
New treatment option for Radio Dermatitis
Official title Polarized Light Therapy for Radiation Dermatitis in Breast Cancer
ClinicalTrials.gov ID: NCT07600957
What this study is testing
- What it's testing
- This assessor-blinded randomized controlled trial aims to evaluate the efficacy of polarized polychromatic non-coherent light therapy as an adjunct to standard skin care in reducing acute radiation dermatitis in women with breast cancer undergoing hypofractionated whole-breast radiotherapy. Participants will be randomly allocated to receive either standard skin care alone or standard care combined with polarized light therapy initiated from the first radiotherapy session.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 35 to 55, women only
You may be able to join if
- Female patients aged 35-55 years.
- Histologically confirmed primary unilateral breast cancer.
- Status post breast-conserving surgery (lumpectomy).
- Planned for hypo fractionated whole-breast irradiation (HFWBI).
- Scheduled to receive a total radiation dose of 40-42.5 Gy delivered in 15-16 fractions over approximately 3 weeks.
You likely can't join if
- Previous radiotherapy to the same breast or thoracic region.
- Bilateral breast cancer.
- Metastatic or advanced systemic disease.
- Prior mastectomy.
- Active skin infection in the irradiated area.
- Pre-existing dermatologic disorders affecting the breast skin (e.g., eczema, psoriasis, dermatitis).
See the full eligibility criteria
- Female patients aged 35-55 years.
- Histologically confirmed primary unilateral breast cancer.
- Status post breast-conserving surgery (lumpectomy).
- Planned for hypo fractionated whole-breast irradiation (HFWBI).
- Scheduled to receive a total radiation dose of 40-42.5 Gy delivered in 15-16 fractions over approximately 3 weeks.
- Ability to understand study procedures and provide written informed consent.
- Previous radiotherapy to the same breast or thoracic region.
- Bilateral breast cancer.
- Metastatic or advanced systemic disease.
- Prior mastectomy.
- Active skin infection in the irradiated area.
- Pre-existing dermatologic disorders affecting the breast skin (e.g., eczema, psoriasis, dermatitis).
- Concurrent chemotherapy during radiotherapy.
- Presence of cardiac pacemaker or implantable electronic device in the treatment field.
- Open wounds or ulceration in the irradiated breast region.
- Any medical condition judged by the investigator to interfere with study participation or outcome assessment.
The study team makes the final eligibility decision.
Where it's taking place
- Banī Suwayf, Egypt
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 35 years to 55 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Banī Suwayf, Egypt. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.